F-star Therapeutics, Inc. Common Stock
FSTX
FSTX was delisted on the 8th of March, 2023.
59 hedge funds and large institutions have $57.8M invested in F-star Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 10 increasing their positions, 19 reducing their positions, and 9 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
67% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 9
63% more capital invested
Capital invested by funds: $35.5M → $57.8M (+$22.3M)
9% more funds holding
Funds holding: 54 → 59 (+5)
47% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 19
93% less call options, than puts
Call options by funds: $331K | Put options by funds: $4.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$5.54M |
| 2 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$3.03M |
| 3 |
QOP
Quinn Opportunity Partners
Charlottesville,
Virginia
|
+$995K |
| 4 |
VAM
Vazirani Asset Management
New York
|
+$692K |
| 5 |
BCM
BCK Capital Management
Stamford,
Connecticut
|
+$473K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DMKJ
David M. Knott Jr
|
-$1.21M |
| 2 |
AA
AlphaCentric Advisors
San Juan,
Puerto Rico
|
-$845K |
| 3 |
E
Ergoteles
New York
|
-$760K |
| 4 |
HF
HRT Financial
New York
|
-$558K |
| 5 |
Russell Investments Group
London,
United Kingdom
|
-$324K |
FSTX Hedge Fund Activity: Q4 2022 in Review
59 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q4 2022, worth a combined $57.8M — up 63% from $35.5M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new FSTX positions and 9 closed out — a net gain of 6 holders — while 10 added to existing stakes and 19 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $5.54M. The largest seller was David M. Knott Jr, exiting entirely with an estimated $1.21M sold.
- 59 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q4 2022, up from 54 in Q3 2022.
- Funds reported $57.8M of F-star Therapeutics, Inc. Common Stock stock for Q4 2022, up 63% quarter-over-quarter.
- 15 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q4 2022 and 9 closed out, a net change of +6 holders.
- The largest F-star Therapeutics, Inc. Common Stock buyer in Q4 2022 was Armistice Capital, an estimated $5.54M added.
- The largest F-star Therapeutics, Inc. Common Stock seller in Q4 2022 was David M. Knott Jr, an estimated $1.21M sold.
Based on aggregated 13F filings for Q4 2022.